This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences and Health Care Industry

Life science and Health careDeloitte Global Life Sciences and Health Care Practice

Deloitte Global has 7,600 professionals serving the Life Sciences and Health Care industry. Deloitte’s clients include all of the 10 largest global pharmaceutical manufacturers, nine of the 10 largest global medical equipment manufacturers, eight of the 10 largest global biotechnology companies and 80% of the 2013 Life Sciences and Health Care in the Fortune Global 500 list.

Deloitte China Life Sciences and Health Care practice

In China, Deloitte has an elite team of over 600 bilingual professionals. Our diverse cultural backgrounds, professional knowledge and local understanding of industry-specific challenges within China enable our team to effectively communicate with clients, thoroughly understand their business needs and provide comprehensive solutions that meet their goals.

Deloitte China Life Sciences and Health Care practice covers two major sectors:

Life Sciences

• Biotechnology
• Pharmaceuticals
• Medical Distribution Companies
• Medical Devices Manufacturer
• Medical Devices Distributor / Agency
• Inspection and Testing Institutions
• Material / Spare Parts Provider

Health Care

• Hospitals & Health Systems
• Academic Medical Organisations / Physician Groups
• Long Term Care / Aging House
• Commercial Health Plans
• Government Sponsored Health Plans
• Health Administrators

More Featured insight

  • Fortune favors the bold: Unlocking the future of China’s pharmaceutical market
    Exploring the key events of the past 24 months in China's health care market and four key themes pharmaceutical companies should consider as they think about their future in China.
  • Insider analysis from Monitor Deloitte on new commercial models For China’s tier 2 market
    Growth and margins are slowing or declining in the top tier market. Expanding into the geographically dispersed and fragmented Tier 2 market and serving the market cost effectively are top agenda for MNCs.
  • Top JV Issues for Pharmaceutical Companies in China
    Establishing a joint venture in China is a complex and time-consuming task, and there is no guarantee of success or even survival. It is critical for pharma executives to fully understand various pitfalls and manage the partnership for success.
  • 2014 Global Health Care Outlook
    The report examines the current state of the global health care sector.
  • 2014 Global Life Sciences Outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • Corruption risk in the Chinese Pharmaceutical market
    The report illustrates the issues and challenges you may face as this situation unfolds, and the importance of having a strategy to address potential problems.
  • Transforming Medical Affairs in China
    Rethinking the role and effectiveness of the Medical Affairs function has become an urgent priority for pharmaceutical companies in China. The report presents our perspective on these challenges and how they can be successfully overcome.
  • Health care reform and life sciences: Threat, opportunity or both?
    Exploring how nearly 300 senior life science executives are meeting the challenges and opportunities of global health care reforms, and the national differences through case studies of China, Brazil and Germany.
  • The next phase: Opportunities in China's pharmaceuticals market
    This report focuses in particular on pharmaceuticals companies, both domestic and foreign, and their activities in the China market—all from the viewpoint of prospective investors.
  • 2011 survey of health care consumers in China
    China joined the survey for the first time. A study of Chinese health care consumers' attitudes, behaviors and unmet needs in six key areas.

 

 

 

Contact us

  • ExternalURL
    Yvonne Wu
    Managing Partner, China Life Sciences and Health Care Industry
  • ExternalURL
    Jill Zhu
    Program Manager, China Life Sciences and Health Care Industry

Related links

  • ExternalURL
    Deloitte Global Life Sciences and Health Care
    Global reach that you can count on
  • ExternalURL
    Deloitte China services
    Our full range of services
Share your comments

 

Stay connected